Oprelvekin
Alternative Names: Interleukin-11; Neumega; Recombinant human-interleukin-11; rhIL-11; SCH-53620; YM-294Latest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Class Antineoplastics; Chemoprotectants; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 11 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Thrombocytopenia
- Discontinued Bacteraemia; Crohn's disease; Graft-versus-host disease; Inflammatory bowel diseases; Mucositis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 04 Nov 2004 Discontinued - Preregistration for Thrombocytopenia in Japan (SC)